Startup Xaira Therapeutics, backed by $1 billion in funding, will leverage artificial intelligence for drug discovery and development, with AI research to be conducted at the lab of co-founder David Baker, director of the University of Washington School of Medicine's Institute for Protein Design. Xaira's management team includes co-founder Hetu Kamisetty and former Genentech executives Marc Tessier-Lavigne, Arvind Rajpal and Don Kirkpatrick.